Biotechnology company, Atomic AI, is announcing its launch along with a $35 million dollars Series A round led by Playground Global. The startup offers a platform that fuses AI technology with structural biology to discover and design new RNA drugs. Atomic says the process aims to enable the creation of medicines for so-called undruggable diseases, which are diseases that can't typically be targeted by pharmaceuticals. Raphael Townshend, founder and CEO of Atomic AI, joined Cheddar News' Closing Bell to discuss.